Cover Image

PAPERBACK
$43.50



View/Hide Left Panel

Pathogen (Target Population)

Type of Vaccine

Individuals Entering Target Populationa

Delay in Vaccination Benefits

Neisseria meningitidis

(Infants, 3 to 6 months)

Conjugated capsular polysaccharides, Groups A,C,Y, and W135

Endemic—birth cohort: 115.1 million

Epidemic—birth cohort in areas subject to epidemics: 13.1 million

Endemic—probable age of vaccination

(<1 year) to peak of disease (2 years), i.e., approx. 1 year. Epidemic—probable age of vacc. to peak of disease (approx. 11 years), i.e., approx. 6 years

Parainfluenza viruses

(Infants)

Trivalent, subunit vaccine (which must contain fusion proteins)

Birth cohort: 115.1 million

Probable age of vaccination

(<1 year) to peak of illness (2 years), i.e., approx. 1 year

Plasmodium spp.

(All infants at risk, military personnel, travelers)

Plasmodium falciparum, synthetic or recombinant sporozoite antigen preparation

Birth cohort in major areas of occurrence: 78 million

Probable age of vaccination

(<1 year) to peak of most severe consequences (i.e., death in young children 2–5 years) i.e., approx. 3 years

Multivalent synthetic or recombinant sporozoite antigen preparation (P. falciparum, P. vivax, P. ovale, P. malariae)

Rabies virus (Individuals at high risk, plus post-exposure prophylaxis)

Vero cell

Yearly number of individuals requiring post-exposure prophylaxis as estimated by WHO: 5.6 million

Less than 1 year

(As above)

Glycoprotein produced by rDNA technology in mammalian cells

Yearly number of individuals requiring post-exposure prophylaxis as estimated by WHO: 5.6 million

Less than 1 year

(Birth cohort in areas of high risk)

Attenuated live vector virus containing gene for protective glycoprotein antigen

Birth cohort in high risk areas: approximately 53 million

Probable age of vaccination 2–4 years Highest risk group is assumed to be teenagers; delay in benefits is assumed to be 10 years

Respiratory syncytial virus

(Infants at earliest possible age)

Polypeptides produced by recombinant DNA technology

Birth cohort: 115.1 million

Probable age of vaccination

(<1 year) to peak of illness (2 years), i.e., approx. 1 year

Attenuated live virus



The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement